Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo

Paris Margaritis, Elise Roy, Armida Faella, Harre D. Downey, Lacramioara Ivanciu, Giulia Pavani, Shangzhen Zhou, Ralph M. Bunte, Katherine A. High

Blood (2011) 117 (15): 3974–3982.

https://doi.org/10.1182/blood-2010-09-309732

Published: 2011

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Continuous Expression of An Improved Variant of FVIIa On Murine Hemostasis with or without Inhibitors to Human Factor IX.

Elise Roy, Armida Faella, Harre Downey, Lacramioara Ivanciu, Ph.D., Shangzhen Zhou, Katherine A. High, MD, Paris Margaritis, D.Phil

Blood (2009) 114 (22): 2466.

https://doi.org/10.1182/blood.V114.22.2466.2466

Published: 2009

Journal Articles

Successful treatment of canine hemophilia by continuous expression of canine FVIIa

Paris Margaritis, Elise Roy, Majed N. Aljamali, Harre D. Downey, Urs Giger, Shangzhen Zhou, Elizabeth Merricks, Aaron Dillow, Mirella Ezban, Timothy C. Nichols, Katherine A. High

Blood (2009) 113 (16): 3682–3689.

https://doi.org/10.1182/blood-2008-07-168377

Published: 2009

Journal Articles

Successful and Safe Treatment of Canine Hemophilia by Continuous Expression of Canine FVIIa: a Model for FVIII/FIX Gene-Based Bypassing Agents

Paris Margaritis, Elise Roy, Majed N Aljamali, Harre Downey, Shangzhen Zhou, Elizabeth Merricks, Aaron Dillow, Timothy C Nichols, Katherine A. High, MD

Blood (2008) 112 (11): lba-4.

https://doi.org/10.1182/blood.V112.11.lba-4.lba-4

Published: 2008

Journal Articles

Gene Transfer of Canine FVIIa Results in Partial Correction of Canine Hemophilia: A Model for FVIII/FIX Gene-Based Bypassing Agents.

Paris Margaritis, PhD, Elise Roy, MS, Harre D. Downey, BS, Shangzen Zhou, PhD, Elizabeth Merricks, Aaron Dillow, Timothy C. Nichols, MD, Katherine A. High, MD

Blood (2007) 110 (11): 195.

https://doi.org/10.1182/blood.V110.11.195.195

Published: 2007

Journal Articles

In Vitro and In Vivo Characterization of a Murine Model of Suppressed Intrinsic Pathway Using a FX Variant: FX Roma .

Elise Roy, MS, Paris Margaritis, PhD, Harre D. Downey, BS, Katherine A. High, MD

Blood (2007) 110 (11): 2697.

https://doi.org/10.1182/blood.V110.11.2697.2697

Published: 2007

Journal Articles

A Murine FVIIa Variant with Increased Tissue Factor-Independent Intrinsic Activity Corrects the Murine Hemophilia B Phenotype Following AAV Administration: Implications for Therapeutic AAV Vector Doses.

Paris Margaritis, PhD, Elise Roy, MS, Katherine A. High, MD

Blood (2006) 108 (11): 3276.

https://doi.org/10.1182/blood.V108.11.3276.3276

Published: 2006

NARROW

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo

Efficacy and Safety of Continuous Expression of An Improved Variant of FVIIa On Murine Hemostasis with or without Inhibitors to Human Factor IX.

Successful treatment of canine hemophilia by continuous expression of canine FVIIa

Successful and Safe Treatment of Canine Hemophilia by Continuous Expression of Canine FVIIa: a Model for FVIII/FIX Gene-Based Bypassing Agents

Gene Transfer of Canine FVIIa Results in Partial Correction of Canine Hemophilia: A Model for FVIII/FIX Gene-Based Bypassing Agents.

In Vitro and In Vivo Characterization of a Murine Model of Suppressed Intrinsic Pathway Using a FX Variant: FX Roma .

A Murine FVIIa Variant with Increased Tissue Factor-Independent Intrinsic Activity Corrects the Murine Hemophilia B Phenotype Following AAV Administration: Implications for Therapeutic AAV Vector Doses.

Email alerts

ASH Publications

American Society of Hematology

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo

Efficacy and Safety of Continuous Expression of An Improved Variant of FVIIa On Murine Hemostasis with or without Inhibitors to Human Factor IX.

Successful treatment of canine hemophilia by continuous expression of canine FVIIa

Successful and Safe Treatment of Canine Hemophilia by Continuous Expression of Canine FVIIa: a Model for FVIII/FIX Gene-Based Bypassing Agents

Gene Transfer of Canine FVIIa Results in Partial Correction of Canine Hemophilia: A Model for FVIII/FIX Gene-Based Bypassing Agents.

In Vitro and In Vivo Characterization of a Murine Model of Suppressed Intrinsic Pathway Using a FX Variant: FX Roma .

A Murine FVIIa Variant with Increased Tissue Factor-Independent Intrinsic Activity Corrects the Murine Hemophilia B Phenotype Following AAV Administration: Implications for Therapeutic AAV Vector Doses.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only